Compare Gilead Sciences, Inc. (GILD) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs First Trust Cloud Computing ETF — how do they compare? Gilead Sciences, Inc. trades at $149.06 (market cap $182.40B), while First Trust Cloud Computing ETF trades at $172.56 (market cap $3.47B). The key difference: Gilead Sciences, Inc. is far larger — about 52.6× First Trust Cloud Computing ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and First Trust Cloud Computing ETF for 84 Days on average.
| GILD | SKYY | |
|---|---|---|
Market Cap | $182.40B | $3.47B |
Volume | 4,469,821 | 176,159 |
Sector | Health | — |
52-Week High | $155.80 | $171.01 |
52-Week Low | $116.74 | $104.16 |
Typical Hold Time | 111 Days | 84 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
SKYY (First Trust Cloud Computing ETF) trades at $171.75, up 0.57% today and recently hitting a new 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF benefits from strong secular trends in cloud computing and AI infrastructure spending, with recent news highlighting institutional position adjustments and positive sector outlook.
The outlook remains positive given cloud computing's growth trajectory and AI-driven demand, though valuation metrics are unavailable for analysis. Risks include sector concentration and market volatility. Institutional activity shows mixed signals with some trimming positions while sector analysts maintain optimistic coverage on cloud computing infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
